Company / Profit Margin
ADMA Biologics, Inc. Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
28.8%
FY2025
5-year range
-88.5% / 46.4%
FY2021-FY2025
Trend
-37.9%
vs FY2024
Sector context
#20 of 145
Health Care
What the data says
ADMA Biologics, Inc.'s profit margin of 28.8% is higher than 86% of companies in the Health Care sector (FY2025). Profit Margin has fluctuated over the past 10 years, ranging from -387.1% in FY2018 to 46.4% in FY2024.
Based on SEC 10-K filings.
28.8% in FY2025 with a 5-year CAGR of +208.2%. Top quartile in the Health Care sector.
Improved from -10.9% to 28.8% over the past 2 years.
Health Care sector context is included.
Profit Margin over time
Growth rates
- 3-Year Change
- +117.3pp
- 5-Year Change
- +208.2pp
- 10-Year Change
- -
Sector benchmark
Top 14% in Health CareTop 14% of 145This company 28.8% Sector average -792.7%
▼
+103.6% above sector average
Key checks
Key Insights
- In FY2025, profit margin decreased 37.9% year-over-year.
- Currently 821.5pp above the Health Care sector average.
- Peak profit margin was recorded in FY2024.
- Lowest profit margin in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 28.8% | -37.9% |
| FY2024 | 46.4% | +523.7% |
| FY2023 | -10.9% | +87.6% |
| FY2022 | -88.5% | +0.0% |
| FY2021 | -88.5% | +50.7% |
| FY2020 | -179.4% | -9.1% |
| FY2019 | -164.5% | +57.5% |
| FY2018 | -387.1% | -111.5% |
| FY2017 | -183.1% | +0.0% |
| FY2016 | -183.1% | +35.6% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026